Celldex Debt To Equity from 2010 to 2024

CLDX Stock  USD 26.51  0.11  0.42%   
Celldex Therapeutics Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity will likely drop to 0 in 2024. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.00376074
Current Value
0.003573
Quarterly Volatility
0.03379088
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Celldex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celldex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 5.8 M or Selling General Administrative of 29.4 M, as well as many indicators such as Price To Sales Ratio of 293, Dividend Yield of 0.0 or PTB Ratio of 3.62. Celldex financial statements analysis is a perfect complement when working with Celldex Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Celldex Therapeutics Correlation against competitors.
For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Latest Celldex Therapeutics' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Celldex Therapeutics over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Celldex Therapeutics' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Celldex Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.01 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Celldex Debt To Equity Regression Statistics

Arithmetic Mean0.03
Geometric Mean0.01
Coefficient Of Variation125.85
Mean Deviation0.02
Median0.02
Standard Deviation0.03
Sample Variance0
Range0.1148
R-Value(0.58)
Mean Square Error0.0008
R-Squared0.34
Significance0.02
Slope(0)
Total Sum of Squares0.02

Celldex Debt To Equity History

2024 0.003573
2023 0.003761
2022 0.00443
2021 0.004162
2020 0.006338
2019 0.0207
2018 0.0365

About Celldex Therapeutics Financial Statements

Celldex Therapeutics investors use historical fundamental indicators, such as Celldex Therapeutics' Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Celldex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.